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Abstract
Background: Genetic variation at loci influencing adult levels of HbF have been shown to modify the clinical course of sickle
cell disease (SCD). Data on this important aspect of SCD have not yet been reported from West Africa. We investigated the
relationship between HbF levels and the relevant genetic loci in 610 patients with SCD (98% HbSS homozygotes) from
Cameroon, and compared the results to a well-characterized African-American cohort.
Methods and Findings: Socio-demographic and clinical features were collected and medical records reviewed. Only
patients .5 years old, who had not received a blood transfusion or treatment with hydroxyurea were included. Hemoglobin
electrophoresis and a full blood count were conducted upon arrival at the hospital. RFLP-PCR was used to describe the HBB
gene haplotypes. SNaPshot PCR, Capillary electrophoresis and cycle sequencing were used for the genotyping of 10
selected SNPs. Genetic analysis was performed with PLINK software and statistical models in the statistical package R. Allele
frequencies of relevant variants at BCL11A were similar to those detected in African Americans; although the relationships
with Hb F were significant (p ,.001), they explained substantially less of the variance in HbF than was observed among
African Americans (, 2% vs 10%). SNPs in HBS1L-MYB region (HMIP) likewise had a significant impact on HbF, however, we
did not find an association between HbF and the variations in HBB cluster and OR51B5/6 locus on chromosome 11p, due in
part to the virtual absence of the Senegal and Indian Arab haplotypes. We also found evidence that selected SNPs in HBS1L-
MYB region (HMIP) and BCL11A affect both other hematological indices and rates of hospitalization.
Conclusions: This study has confirmed the associations of SNPs in BCL11A and HBS1L-MYB and fetal haemoglobin in
Cameroonian SCA patients; hematological indices and hospitalization rates were also associated with specific allelic variants.
Citation: Wonkam A, Ngo Bitoungui VJ, Vorster AA, Ramesar R, Cooper RS, et al. (2014) Association of Variants at BCL11A and HBS1L-MYB with Hemoglobin F and
Hospitalization Rates among Sickle Cell Patients in Cameroon. PLoS ONE 9(3): e92506. doi:10.1371/journal.pone.0092506
Editor: Ana Paula Arez, Instituto de Higiene e Medicina Tropical, Portugal
Received January 12, 2014; Accepted February 21, 2014; Published March 25, 2014
Copyright:  2014 Wonkam et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The molecular experiments of the study were funded by the National Health Laboratory Services (NHLS), South Africa; the University of Cape Town
(UCT) Research Committee and Carnegie Research Development Grant, South Africa. The students’ bursaries were supported by the Third World Academy of
Sciences (TWAS). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ambroise.wonkam@uct.ac.za
Introduction
Sickle cell disease (SCD) affects the structure of erythrocytes by
altering the normal biconcave shape to a crescent. During this
process the hemoglobin S (HbS) mutation leads to polymerization
and precipitation of hemoglobin during deoxygenation or
dehydration resulting in sickling, abnormal adhesion of leukocytes
and platelets, inducing inflammation, hypercoagulation, hemolysis
and hypoxia, in addition to microvascular obstruction, and
ultimately organ damage [1]. SCD is prevalent among indigenous
populations in tropical regions of Africa and Asia; 305,800 births
with SCD are estimated to occur annually, nearly two-third of
which take place in Africa. Sickle Cell Anaemia (SCA; the
homozygous HbSS state) is by far the most prevalent and severe
form of SCD [2]. Only limited early detection and treatment
initiatives have been implemented in Africa and as consequence
death rates are high before the age of 5 years in this region [3].
Cameroon has a population about 20 million inhabitants and a
growth rates of 3% per annum; the carrier frequency of SCA
ranges from 8 to 34% [4]. Cameroon has developed a national
control program for SCA, although at present it remains a policy
document without implementation; provision of neonatal screen-
ing and development of specialized centers for lifelong medical
care and surveillance have yet to become part of the health system
[5]. Universal medical insurance coverage does not exist, and care
of SCA patients is therefore dependent on financial support and
care-giving by family members. Poverty in Cameroon affects more
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than 50% of the rural population and up to 30% of the urban
population [6], which in turn means that the financial burden of
medical care for SCA can often not be met [5] and patients
frequently suffer exceptionally severe SCD sequelae such as of
stroke [7] and neurocognitive compromise [8].
SCA is genetically characterised by a single point mutation in
the globin locus, however, there are additional genetic factors that
modulate the clinical course of this disease and patients manifest
widely varying degrees of severity. Several genomic loci have now
been identified that are associated with increased levels of fetal
haemoglobin (HbF) and as a consequence influence the clinical
course of SCA [9–11]. HbF is a highly heritable trait; based on
samples of Europeans with a normal hematocrit 89% of the
variation is genetically determined [12]. To date at least 3
quantitative trait loci (QTL) have been shown to be associated
with persistence of elevated HbF and account for 20–50% of the
inter-individual variation in HbF. These loci include the combined
XmnI-158 and OR51B5/6 locus on chromosome 11p15.4 [13], the
HBS1L-MYB intergenic polymorphism (HMIP) locus on chromo-
some 6q23.3 [14], which may reflect the role of a single variant,
and the BCL11A locus on chromosome 2q16.1 [15,16]. In order to
stimulate HbF expression, experimental and clinical work resulted
in adoption of hydroxyurea as adjunct treatment for high risk SCA
patients [17], and this is now widely accepted therapy. Moreover,
other investigators have recently demonstrated that inactivation of
BCL11A in an SCD transgenic mouse model completely eliminates
the hematologic and pathologic defects associated with SCD
through induction of high-level pancellular HbF [18].
SCA was the first molecular disease to be recognized in medical
practice and the description of the DNA-protein relationship
underlying this disorder was a milestone in molecular medicine. It
is both ironic and unfortunate, therefore, that the powerful new
tools of genomics have not been applied to research on SCA on
the African continent. To the best of our knowledge, only one
study has reported data on selected genetic effects associated with
increased level of HbF amongst SCA patients in sub-Saharan
Africa [19] and no studies on the association of these SNPs with
clinical outcomes has yet been reported from the region. The
sickle mutation exists in Africa on diverse genetic haplotype
backgrounds [20] and geographically separate African populations
may vary in the effects of linked genetic variants found on specific
haplotypes. Studies of SCA in African sub-populations could
therefore potentially lead to important new findings about factors
that influence the disease phenotype. The aim of this study was to
explore the frequency and influence of 10 SNPs known to
influence HbF within the HMIP, BCL11A, XmnI-158 and
OR51B5/6 loci amongst a group of Cameroonian SCA patients
and to compare these data to a well described cohort of African-




The study was performed in accordance with the guidelines of
the Helsinki Declaration. Ethical approval was given by the
National Ethical Committee Ministry of Public Health, Republic
of Cameroon (No 033/CNE/DNM/07); and the University of
Cape Town, Faculty of Health Sciences Human Research Ethics
Committee (HREC RE: 132/2010). Written and signed informed
consent was obtained from the adult participants who were 18
years or older, and for the children consent was obtained from
parents/guardians with an assent from the participants older than
seven years of age.
Patients and assessment of clinical events
The study was conducted at the Yaoundé Central Hospital and
Laquintinie Hospital in Douala, the primary port and second
largest city in Cameroon. Socio-demographic and clinical data
were collected by means of a structured questionnaire. Parents/
guardians as well as adult SCA patients were interviewed; patients’
medical records were reviewed, to delineate their clinical features
over the past three years. Specifically, the occurrences of vaso-
occlusive painful crisis (VOC), hospital outpatient visits, hospital-
isations, overt strokes, blood transfusions and administration of
hydroxyurea were recorded. VOC events were defined as episodes
that could not be attributed to causes other than SCA and
required a hospital visit and treatment with prescription analgesics.
Anthropomorphic variables (body mass Index (BMI), and blood
pressures (BP) were measured in the outpatient setting.
The sampling strategy was not restricted to hospital-based
patients in an attempt to avoid the bias that might result from
including only the sickest patients. To accomplish this goal two
SCA patients’ associations in Cameroon were engaged for
collaboration and additional patients were recruited during their
monthly meetings. No incentive was provided for participation in
the study. Only patients who had not received a blood transfusion
or hospitalisation in the past 6 weeks where included. None were
currently treated with hydroxyurea.
Hematological Phenotypes
Hemoglobin electrophoresis and complete routine blood count
of the SCA patients were conducted upon arrival at the hospital.
Two methods of HbF detection were employed in this study for
successive groups of patients; initially, as a result of limited
capacity, the alkali denaturation test (ADT) was used, and
subsequently high performance liquid chromatography (HPLC)
was performed. HbF determinations were performed at the
hematological laboratory of the Centre Pasteur in Yaoundé; we
excluded from the analysis measurements done in patients ,5
years old because HbF levels are not yet stable at this age. HbF
levels were measured by ADT in 344 patients (55.5%). HbF
measurements by HPLC and ADT techniques were found to have
differences in median values (P = 0.001), with ADT yielding the
median value of 11.7% compared to 6.8% for the HPLC method.
As previously reported, HbF was measured in the CSSCD
samples by ADT and HbA2 was measured by Diethylamino
Ethanol column chromatography [21]. For HbF in the CSSCD
study, we also excluded from the analysis measurements done in
patients ,5 years old [9].
Genotypes
Cameroonian patients. DNA samples were extracted from
peripheral blood, following instructions for the commercial kit
(Puregene blood kit (Qiagen, USA) at the molecular diagnostic
laboratory, Gyneco-Obstetric and Paediatric Hospital, Yaoundé,
Cameroon. Genotype analyses were performed in the Division of
Human Genetics, Faculty of Health Sciences, University of Cape
Town.
Molecular Diagnostic Testing for SCA (HbSS). Analysis
for presence of the sickle mutation was carried out on 200 ng DNA
by PCR, on a thermocycler (BIORAD, USA) to amplify a 770 bp
segment of the b-globin gene, followed by Dde I (GIBCO-BRL,
USA) restriction analysis of the PCR product. Only patients SCD-
HbSS were included in the analysis, according to a previously
reported method [22].
Haplotyping of the b-globin gene cluster. Five restriction
fragment length polymorphism (RFLP) regions in the b-globin
gene cluster were amplified using published primers and methods
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to analyse the XmnI (5’Gc), HindIII (Gc), HindIII (Ac), HincII
(3̇’Yb), and HinfI (5’b) [23]. RFLP sites and the fragments were
visualised by agarose gel electrophoresis; b-globin gene haplotypes
were defined by examining the combination of the restriction sites.
SNPs genotyping in the HMIP, BCL11A, XmnI-158 and
OR51B5/6 loci: For the purpose of obtaining genotype for
variants associated with HbF levels that had been previously
identified in SCA patients, ten regions containing specific SNPs
were amplified: viz, for the BCL11A locus, SNPs rs11886868 and
rs4671393; for the HMIP1/2 loci: SNPs rs28384513, rs9376090,
rs9399137, rs9389269; rs9402686 and rs9494142; for the
OR51B5/6 loci: SNP rs5006884, for HBG loci, SNP rs7482144.
PCR was performed to determine genotypes using SNaPshot
multiplex ready reaction mix (Applied Biosystems, California,
USA) as previously reported [24]. For SNP genotyping, the
accuracy of the SNaPshot method was shown to be comparable to
Biplex Invader and Pyrosequencing, while lower in cost when
multiplex reactions are used [24]. Two singleplex reactions
allowed the amplification of SNPs rs7482144 and rs9399137;
and three multiplex reactions allowed the amplification of
rs11868668, rs28384513 and rs9389269 (mutiplex1); rs9376090,
rs9402686 and rs5006884 (mutiplex 2); rs9494142 and rs4671393
(mutiplex 3).
Capillary electrophoresis was used for the determination of
genotype; 0.5 ml treated SNaPshot reaction mixture was mixed
with 5 ml HiDi formamide (Applied Biosystems) and 0.2 ml
GeneScan -120 Liz size standard. This mixture was loaded onto
a Micro Amp 96 well reaction Plate (Applied Biosystems) and
analysed using the GeneScan-120 Liz and run model at
E5_36_POP7.
Cycle sequencing. For Cameroonian samples, we confirmed
the genotyping results for both SNaPshot and RFLP-PCR by
sequencing a sub-set of samples (10%). Sequencing was performed
using BigDye terminator mix (Promega, Wisconsin, USA) and 5X
BigDye terminating buffer (Promega, Wisconsin, USA). Cycle
sequencing was then performed on the Applied Biosystems
thermal cycler (Gene Amp PCR system 9700). An electrophero-
gram was generated using sequence analysis software and
imported into Bioedit Sequence alignment editor 7.0.0 (Tom
Hall, Isis Pharmaceuticals, Inc.) for the alignment of the sequence
with a reference sequence to identify the SNP of interest.
CSSCD patients. For the CSSCD patients, all DNA
genotyping was performed by using the mass spectrometry-based
MassArray iPLEX platform from Sequenom as previously
reported [9]. For SNPs passing quality control, the genotyping
success rate was .93% and the consensus error rate, estimated
from replicates, was ,0.3%.
Statistical analysis
Descriptive statistics were obtained for all quantitative data
using SPSS (IBM, USA version 21.0). Normality was confirmed by
the Shapiro-Wilk Test followed, by the use of parametric (Chi-
squared test and t-test) or non-parametric tests (Mann-Whitney U
test for 2 samples or the Kruskal-Wallis ONE way ANOVA for
more than 2 samples). Significance was set at the 0.05 level.
Genetic analysis was performed with PLINK software [25], testing
only the additive genetic model under a linear regression
framework. For quality control, a Hardy-Weinberg test was
performed on all genotype results: two SNPs were dropped
because of significant violation of HWE (rs1188686 in BCL11A,
MAF 0.31; HWE P-value: 0.000609; and rs9389269 in the
HBS1L-MYB locus, MAF: 0.17; HWE P-value: 2.42E-05). A third
SNP was monomorphic (rs9376090 in the HBS1L-MYB locus, all
the patients were T/T homozygous). In the CSSCD patients, on
Hardy-Weinberg equilibrium test, P value was .0.05 for all SNPs,
except for the -158 (G.A) XmnI polymorphism in the Gc-globin
(HBG2) gene promoter (rs7482144), which was in disequilibrium
(P = 0.002) [9]. For a polymorphism in LD (linkage disequilib-
rium) with the sickle cell mutation, this finding is expected in a
population of SCD patients [9].
When several SNPs were genotyped at the same locus, we used
conditional analysis and stepwise regression to determine whether
one or more independent association signals were present.
To correct for the skewness of the HbF distribution, we log10-
transformed and normalized the data to obtain the quantitative
trait used in the association analysis (after correcting for age,
gender, and electrophoresis technique and history of transfusion).
Statistical models to investigate the relationship between HbF-
associated SNPs and SCD complications were conducted in the
statistical package R, version 2.5.1.
Results
Socio-demographic and Hematological variables
The description of the study sample is presented in Table 1.
Among the 610 patients 50.3% were female; the mean age (6 SD)
of patients was 17.3610 years (range: 5–54 years), and the
majority of patients were children aged 5–10 years (32.2%;
n = 196) or adolescents 11–20 years (50%; n = 305). Patients lived
mostly in the urban areas of Yaoundé and Douala (93%; n = 567),
the two largest cities in Cameroon. Among the participants, 41%
(n = 238), 45.6% (n = 265) and 13.2% (n = 78) attended formal
primary, secondary or tertiary education levels, respectively.
Marital status of parents was distributed as follows: married
(58%; n = 235), single (28%; n = 113), widows (9%, n = 36) and
divorced (5%; n = 21). Forty two percent (n = 158) of fathers and
23% (n = 108) of mothers were formally employed, while 41%
(n = 153) of fathers and 39% (n = 183) of mothers were working in
the informal sector. The majority of parents (75%) earned monthly
direct incomes that were , 300 USD. The median age at
diagnosis of SCA, based on haemoglobin electrophoresis, was 3
years (range: 1month - 29 years). Only 31% (n = 180) of patients
were diagnosed before their first year of life.
After molecular analysis, the vast majority of patients were
determined to have SCA (HbSS) (ie, 97.4%; n = 594); 15 (2.4%)
patients were HbS-b thalassemia and one patient had an HbSC
genotype.
There were no significant differences among the socio-
demographic variables (marital status of parents, employment
status, ,300 USD direct revenue; urban vs. rural), in association
with HbF levels or in association with the clinical events (number
of VOC, number of hospital attendance or number of hospital-
isations, overt strokes). The hematological parameters were
generally comparable to those of African Americans in the
CSSCD; the WBC count and the occurrence of VOC were
somewhat more frequent in the Cameroonians (Table 1).
Haplotypes in the beta-globin gene cluster
Based on analysis of 1082 chromosomes, the allele frequencies
of various haplotypes in the beta-globin genes cluster showed that
Benin (74%; n = 799) and Cameroon (19%; n = 207) were most
prevalent forms, followed by atypical haplotype (6%; n = 66).
Bantu (n = 5); Senegal (n = 3) and Indian-Arab (n = 2) alleles were
very rare.
In combination, the Benin/Benin haplotypes represented 57%
(n = 307), Benin/Cameroon 25% (n = 137), Benin/atypical 8%
(n = 45) and Cameroon/Cameroon 5% (n = 26) haplotypes were
most prevalent. There were no significant differences in the
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association with clinical events or HbF levels among the haplotype
combinations.
Association of Genetic Variants to HbF Levels
We did not replicate the association of rs7482144 in HBG2 to
the HbF levels. The adjacent rs5006884 OR51B5/6, was also not
significantly associated to HbF level in Cameroonian SCA patients
(Table 2). On the other hand, the two principal known HbF loci
were significantly associated in the study patients (Table 2). The
effect of minor alleles at this these loci resulted either in a
depression of mean HbF values (rs28384513, HBS1L-MYB), or an
increase in HbF (rs4671393 in BCL11A; rs9399137 and rs9494142
in HBS1L-MYB) (figure 1). As previously reported in African
Americans at the BCL11A loci, when we conditioned the
association analysis on rs4671393, rs11886868 was no longer
significant, suggesting that these markers tag the same causal
polymorphism n this Cameroonian SCA cohort.
The largest allelic effect (0.41, Table 2) in the Cameroonian
patients was detected at the HBS1L-MYB locus, rs9399137;
leading to changes in median values of HbF of 10.6%, 10.3%
and 8.7% for the C/C, C/T and TT alleles, respectively. We
further explored whether the multiple variants at the HBS1L-MYB
locus represented independent signals of association. Using
stepwise regression, we found that rs28384513, rs9399137,
rs9376090, rs9389269 rs9402686 and rs9494142 are independent
association signals in the Cameroonian sample (Table S1 and
Figure S1).
We disaggregated the patient sample, based on the HbF
assessment technique (ADT vs HPLC), and found that the
significant associations with HF levels, examined independently,
were present in both sub-groups studied using the different assay
methods, in rs11886868 (BCL11A), rs4671393 (BCL11A),
rs28384513 (HMIP 1) and rs9494142 (HMIP 2) (Table S2).
HbF-associated variants and hematological parameters
We tested correlations between the 10 HbF-associated SNPs
and various blood cell parameters [RBC count, WBC count, mean
corpuscular volume (MCV), mean corpuscular hemoglobin
(MCH), platelet count, and monocyte levels]. BCL11A
rs4671393 was associated with a wide range of haematological
indices (Table 3). In addition, rs9402686 (HMIP 2) was
significantly associated with platelet count; rs28384513 (HMIP 1)
with WBC counts, and rs9399137 (HMIP 2) with Hb levels,
rs9402686 (HMIP 2) and rs9494142 (HMIP 2) were both
associated with MCV.
Effect of HbF-associated variants on pain crises and rate
of hospitalization
Two SNPs [rs28384513 (HMIP 1) and rs9494142 (HMIP 2)]
were associated with the number of hospitalisations (P = 0.028 and
P = 0.04, respectively, independent of HbF level and various socio-
demographical parameters (figure 2; Table S3). We did not,
however, find an association between the genotyped SNPs and the
numbers of VOC, and overt stroke episodes. In addition, there
was no differential in MAF in the three loci across various age
ranges suggesting that there is not a strong selective advantage for
these loci.
Discussion
Considerable progress has been made in understanding disease
modifying genetic factors in SCD, prompting speculation that this
information may be of potential therapeutic value. In an earlier
study, Thein and colleagues concluded that at least three
independent genetic variants (rs28384513, rs9399137 and
rs6929404) explain the linkage peak observed at 6q23 in the
HBS1L-MYB intergenic region associated with HbF levels [14]. An
association signal with HbF levels in the HBS1L-MYB intergenic
region was also identified in a large non-anemic Sardinian cohort
Table 1. Cohorts’ description.
Variables Cameroon CSSCD
N Mean±SD N Mean±SD
M/F 303/307 682/593
Age (Yrs) 610 17.3610 1275 14.5612.1
RBC (1012/L) 610 2.860.7 1275 2.860.6
Hb (g/dl) 610 7.861.6 1275 6.464.7
MCV (fl) 610 84.469.9 1275 89.469.0
MCHC (g/dl) 610 34.063.8 1275 30.162.9
WBC (109/l) 610 13.765.6 1275 11.962.6
Monocytes (109/l) 610 1.561 1275 0.760.5
Pl atelets (109/l) 610 374.66123 1275 4426151
HbA2 (%) HPLC* 244 3.361.3 1275 2.960.6
HbF (%) (HPLC)* 244 7.564.8 1275 6.364.6
N VOC/Yr 572 363 1275 0.761.4
N hospital attendance (per Yr) 608 2.263.2 NA
N hospital admission (per Yr) 606 2.363 NA
N patients with Strokes 25/608 4.1% 46/1229 3.6%
*Hb electrophoresis was also obtained from 344 patients (55.5%) using alkali denaturation test (ADT), with a mean of 11.469.4 for HbF and 4.162.1 for HbA2 levels. For
the analysis, to correct for the skewness of the HbF distribution, we log10-transformed and normalized the data to obtain (after correcting for age, gender, and
electrophoresis technique and history of transfusion) the quantitative trait used in the association analysis. NA = Not Applicable.
doi:10.1371/journal.pone.0092506.t001
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[26]. Lettre et al. [9] genotyped SNPs rs28384513 and rs9399137,
originally reported by Thein et al. [14] as well as three SNPs
reported in the Sardinian study (rs7776054, rs9389268, and
rs4895441), in the US CSSCD and a Brazilian SCD cohort and
replicated the association with HbF levels [9]. Moreover, Lettre et
al. also explored the intronic SNP in BCL11A, rs11886868, that
strongly correlates with HbF levels in the CSSCD and confirmed
that rs4671393 in BCL11A provides a strong signal of association
with HbF levels in SCD populations [9]. In a Tanzanian SCD
cohort, SNPs in HBS1L-MYB and BCL11A were also found to
have a significant impact on the HbF level [19]. Most recently,
researchers found that common genetic variation at BCL11A
associated with HbF levels lies in noncoding sequences associated
with an erythroid enhancer chromatin signature, this led to the
suggestion that the GWAS-marked BCL11A enhancer represents
an attractive target for therapeutic genome engineering for the b-
hemoglobinopathies [16].
In the present study, the first to our knowledge examining these
genetic relationships in West Africans, we examined the effect of
10 common genetic polymorphisms on HbF and various clinical
outcomes in SCA patients from Cameroon. We have confirmed
robust genetic associations in BCL11A and HBS1L-MYB intergenic
region loci, as previously reported in African Americans and Afro-
Brazilians [9] and Tanzanians [19]. In the CSSCD, five SNPs
explained .20% of residual HbF variation; in the present study 4
SNPs explained about 10% of HbF variation. As a correlate, in the
present study, we found much lower effect sizes for the relevant
markers, especially in the BCL11A loci (Table 2); this could in part
be due to our smaller sample size, or to the reduction in precision
through the use of ADT to measure HbF levels in the majority of
patients [27]. Nevertheless, HbF was measured in the CSSCD
samples in the 1980s by ADT [21]; thus, the difference in effect
size could well be a valid finding that deserves further investiga-
tion; additional fine-mapping of BCL11 should therefore be
considered in future studies. Alternatively, another potential
explanation could be possible poor assay precision of ADT
techniques to measure HbF on the Cameroonian samples. Despite
this possible limitation in HbF phenotyping, the replication of this
level of genetic effect sizes for human complex quantitative traits,
explained using a few genetic polymorphisms, is relatively strong
in comparison to many other quantitative human traits.
As also reported in the present study, multiple variants at the
HBS1L-MYB locus were shown to be independent in African-
American, Afro-Brazilian [9] and Tanzanian SCD patients [19].
Together the polymorphisms explained 8.3% of the variation in
HbF levels in our SCA patients (Table 2). In addition, we have
shown that rs9399137, which acts as a tagging SNP for the HMIP-
2 sub-locus in European populations [14,26], occurred at a low
frequency in this Cameroonian cohort, as noted previously in both
African-American [9] and Tanzanian patients [19]; thus,
Table 2. Fetal hemoglobin association results for SNPs at the BCL11A, HBS1L-MYB, and beta-globin loci in the CSSCD and the
Cameroon sickle cell Anaemia cohort.
















BCL11A rs11886868+ 60720246 T.C 0.31 0.167
(0.06685)
1.4 0.01 0,31 0.524 (0.041 11.8 4.00E-35
BCL11A rs4671393 60720951 G.A 0.30 0.201
(0.07322)




HBS1L-MYB rs28384513 135376209 A.C 0.2 –0.3002
(0.08189)
3 0 0.2 –0.102
(0.049)
0.4 0.04
HBS1L-MYB rs9376090 135411228 T.C 0 NA NA NA NA
HBS1L-MYB rs9399137 135419018 T . C 0.043 0.412
(0.1562)
1.6 0.01 0.06 0.571
(0.086)
3.5 5.00E-11
HBS1L-MYB rs9389269+ 135427159 T.C 0.18 0.09561
(0.08244)
0.3 0.25 ND ND ND ND
HBS1L-MYB rs9402686 135427817 G.A 0.03 0.1447
(0.1887)
0.1 0.44 ND ND ND ND
HBS1L-MYB rs9494142 135431640 T.C 0.11 0.3391
(0.111)
2.1 0 ND ND ND ND
Chr.11
HBG2 rs7482144 5276169 G.A 0.005 –0.05843
(0.5031)
0 0.91 0.07 0.407 (0.080) 2.2 4.00E-07
OR51B5/6 rs5006884 5373251 C.T 0.08 0.04163
(0.1246)
0 0.74 ND ND ND ND
NA = Not applicable. Monomorphic T for the entire sample.
ND = Not determined.
&Chr. = chromosome; Position on NCBI Build 36.1.
$
MAF, minor allele frequency. Minor alleles (positive strand) are given in the parentheses.
#Effect sizes and standard errors are given in standard deviation units for the minor allele.
+On QC, these two SPNs were out of HWE.
doi:10.1371/journal.pone.0092506.t002
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Figure 1. Distribution of fetal hemoglobin levels conditioned on SNP genotypes. Boxes have lines at the lower quartile, median, and upper
quartile. The plot whiskers extend up and down from the median a distance 1.5 times the interquartile range of the boxes (truncated at zero where
necessary). Outliers are the points outside the whiskers indicated as circles.
doi:10.1371/journal.pone.0092506.g001
Table 3. BCL11A (rs4671393) affected a wide range of haematological variables.
GENOTYPES Hemotological variables
RBC (1012/l) Hemoglobin (g/dl) Leucocytes (109/l)
Lymphocytes
(109/l) Platelets (109/l)
rs4671393 (BCL11A) Median P Median P Median P P Median P
CC 2.9 0.02 8.1 0.02 13.1 0.01 6.1 316
CT 2.7 7.8 12.6 5.1 0.02 393 0.02
TT 2.6 7.5 13.6 5.5 385.5
doi:10.1371/journal.pone.0092506.t003
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rs9399137, is not an appropriate proxy for the causative sequence
variant that influences HbF at HMIP-2 on African chromosomes
[28]. However, we report, in the HMIP-2 sub-locus, a much
higher frequency of rs9389269 (0.18) in Cameroonian as
compared to the Tanzanian SCD patients (0.03); this observation
could indicate a high degree of variation in the MAF of this SNP
amongst SCD patients from various African population groups.
Specifically, a 3 bp deletion in perfect LD with rs9399137 in
Figure 2. Association of SNPs in HBS1L-MYB locus and Rates of Hospitalization. Two specific SNPs were associated, with rate of
hospitalization, a potential marker of overall disease severity. Boxes have lines at the lower quartile, median, and upper quartile. Outliers are the
points outside the whiskers indicated as circles.
doi:10.1371/journal.pone.0092506.g002
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Chineses, Europeans and some Africans was reported to be the
candidate functional motif for the HMIP-2 region [29]. But, in the
current Cameroonian samples, rs9389269 was not linked to
rs9399137 (r2 = 0; D’ = 0.138; Table S1). Using 1000Genome
data (Phase I Release Version 3 20101123), we also estimated the
LD between rs9389269 and rs9399137 among Luhya in Webuye
from Kenya (AWK) and Yoruba in Ibadan from Nigeria (YRI);
equally, the results did not indicate any linkage between the two
SNPs in any of the two native African populations: r2 = 0.012;
D’ = 0.233 for AWK and r2 = 0.002; D’ = 1.000 for YRI. Thus,
the candidate for functional motif for the HMIP-2 region in sub-
Saharan African populations deserves to be explored in future
study.
The importance of the HMIP locus in African populations
might therefore have been underestimated by datasets using
markers tailored to European studies [19]. Fine-mapping this locus
could lead to new findings in African patients with SCD.
The association between the XmnI polymorphism (rs7482144)
in the proximal promoter of the c-globin (HBG2) gene and HbF
levels is well documented in SCA patients [9,20]. Due to the
virtual absence of the Senegal and Indian Arab haplotypes that
contain the XmnI variant, we lacked power to replicate the
association of rs7482144 in HBG2 with HbF levels; in the CSSCD,
rs7482144 explains 2.2% of the variation in HbF levels. Other
African populations with the Senegal S haplotype that contains the
rs7482144 SNP would be better suited to study the effects of this
variant. Similarly, a strong signal adjacent to the HBB cluster,
recently detected in African-American patients at rs5006884 in
OR51B5/6 [13], was not significant in our patients. In a report
that included Tanzanian patients, the positive association of HbF
with rs5006884 disappeared when linkage disequilibrium with
rs7482144 was taken into account [19]; this additional HbF locus
does not seem to play an important role in Cameroonians or
Tanzanians.
We also described the prevalence of various haplotypes in the b-
globin gene cluster in Cameroonian SCD patients and reveal that
the Benin haplotype was the most prevalent. It is perhaps
anomalous that the ‘‘Cameroon’’ haplotype, which seems to occur
more frequently in Sudan [30], is not dominant in this population.
The results raise the question of the geographical origin of this
haplotype and also suggest that the detailed geographic distribu-
tion of known sickle haplotypes is still not well established. The
refinement of the molecular structure (i.e. haplotype) in HBB and
migration patterns may yield important information about the
evolutionary history of SCA that could also be clinically relevant
[31]. Contrary to our findings, a recent report argues that the S
haplotype itself (beyond HbF regulation) correlates with severity
[32]. Differences in haplotypes and SNP allele frequencies
between SCA patients from different geographic populations
underscore the need to conduct GWAs in regional sub-Saharan
African populations.
Understanding the effect that HbF-associated variants have
more generally on blood cell production and other parameters will
be important in our efforts to define their biological roles and for
the development of targeted therapies [9,16]. As in African
Americans and Afro-Brazilians studies [9], we replicated the
finding that in combination HBS1L-MYB rs9399137, and BCL11A
rs4671393 SNPs affected platelet counts. In addition BCL11A
rs4671393 SNPs was associated with wider range of hematological
indices in Cameroonians (Table 3), independently of HbF level.
Significant associations of HBS1L-MYB rs9399137 with RBC
indices (RBC count, MCV, MCH), and platelet and monocyte
counts have been reported in healthy non-anemic Europeans [14].
However, in African-American and Brazilian patients Lettre et al.
did not replicate these findings [9].
Previous analyses of the CSSCD dataset showed that increased
HbF levels correlate with less severe complications, fewer pain
crises [33] and improved survival [34]. Having shown that four
sequence variants at two loci influence HbF levels (table 2; Fig. 1),
we next asked whether these SNPs correlate with pain crisis or
stroke in SCA: we did not find any significant associations.
However, two SNPs in HBS1L-MYB were associated with the
number of hospitalisations (figure 2); if confirmed, this could be the
first evidence of the clinical effect that is associated with these
variants. This result could suggest that clinical genotyping of these
variants, and others, yet to be found, may potentially be useful to
risk stratify SCD patients, and to serve as a guide to adjusting
therapeutic and follow up strategies. This finding deserves further
investigation with a larger sample or, ideally, a prospective birth
cohort, to fully appreciate the potential clinical value. Clearly
much remains to be learned about the myriad genetic factors
which modify the course of SCA in Africans.
Limitations and perspectives
A limitation of this study was our inability to use the HPLC
method to measure HbF in all patients; this method was not
available in Cameroon at the beginning of the sample collection.
Even though we have shown that, use of the older assay did not
affect the main outcomes ie, the association of targeted SNPs to
HbF (supplementary data 2). The systematic use of HPLC for HbF
measurement should have allowed more precise estimation of
effect sizes of the genotyped SNPs as well as appropriate
comparison to the other populations of SCA patients. In addition,
phenotyping HbF levels with ADT instead of HPLC in the
majority of samples could have affected the study of the
associations of haplotypes, HbF levels and various clinical events.
Self-report of clinical variables like VOC episodes can also lack
precision and pain tolerance and financial factors could have been
limiting factors for hospital attendance. However, it has also
proven difficult to detect an association of genetic markers with
VOC in affluent settings [9] [35].
Despite the above limitations, this study represent an important
step forward in the understanding of influence of SNPs in
modifying genes on HbF level in Cameroon, and in sub-Saharan
African patients generally. While more than 70% of SCA patients
world-wide live in Africa, most advances in the molecular
understanding and management of SCA have been based on
research conducted in either the US or the UK. Clearly
contemporary research tools must now be widely implemented
in Africa. This study therefore also has a capacity-building
dimension, as it was fully performed from design, molecular
analysis and reporting, on the African continent. Increased
capacity to conduct both clinical and laboratory research on
SCA in Africa could in turn create major collaborative research
opportunities at the regional and international levels.
Conclusion
This study has confirmed the associations of SNPs in BCL11A
and HBS1L-MYB and fetal haemoglobin in Cameroonian SCA
patients and the association of two specific SNPs with rate of
hospitalization, a potential marker of overall disease severity.
These results highlight the differential frequency of SNPs
associated to HbF levels amongst various demographic groups of
SCA patients. Additional data in other African site are needed to
define an updated map of these variants on the continent, as well
as potential new loci that could influence fetal hemoglobin.
BCL11A, HBS1L-MYB and HbF in Sickle Cell Anemia in Cameroon
PLOS ONE | www.plosone.org 8 March 2014 | Volume 9 | Issue 3 | e92506
Supporting Information
Table S1 Linkage analyses of the targeted of SNPs
pairs, studied in the BCL11A and HBS1L-MYB loci.
(DOCX)
Table S2 HbF assessment technique and SNPs Associ-
ations.
(DOCX)
Table S3 Effect of HbF-associated variants on pain
crises and hospitalization rates.
(DOCX)
Figure S1 Analysis showed that rs28384513, rs9399137,
rs9376090, rs9389269 rs9402686 and rs9494142 HBS1L-




Conceived and designed the experiments: AW AAV JN. Performed the
experiments: VJNB AAV RR AW JN. Analyzed the data: AW VJNB AAV
BT RSC GL. Contributed reagents/materials/analysis tools: AW RR JN
BT RSC GL. Wrote the paper: AW RR BT RSC GL. Revised and
approved the manuscript: AW VJNB AAV RR RSC BT GL JN.
References
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